33g blunt end needle (Hamilton Company)
Hamilton Company is a verified supplier 
Hamilton Company manufactures this product 
99
Structured Review
Hamilton Company
33g blunt end needle
33g Blunt End Needle, supplied by Hamilton Company, used in various techniques. Bioz Stars score: 99/100, based on 209 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/33g+blunt+end+needle/33+gauge%2C+Small+Hub+RN+Needle%2C+custom+length+(0%2E4+to+12+in)%2C+point+style+2%2C+3%2C+or+4%2C+6-PK/pm39725189-327-17-20
Average 99 stars, based on 209 article reviews
33g Blunt End Needle, supplied by Hamilton Company, used in various techniques. Bioz Stars score: 99/100, based on 209 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/33g+blunt+end+needle/33+gauge%2C+Small+Hub+RN+Needle%2C+custom+length+(0%2E4+to+12+in)%2C+point+style+2%2C+3%2C+or+4%2C+6-PK/pm39725189-327-17-20
Average 99 stars, based on 209 article reviews
33g blunt end needle - by Bioz Stars,
2026-10
99/100 stars
Images
Related Articles
other:Article Title: Development of Highly Efficient Dual‐AAV Split Adenosine Base Editor for In Vivo Gene Therapy Article Snippet: A Injection:Article Title: Nme 2 Cas9-mediated therapeutic editing in inhibiting angiogenesis after wet age-related macular degeneration onset. Article Snippet: .. The subretinal injection was performed as previously described.19 Briefly, 1-μL AAV8 (9 × 109 VG Nme2Cas9 with sgRNA+ 1 × 109 VG green fluorescent protein (GFP)) was injected into the subretinal region in the 40 s using a Article Title: In vivo adenine base editing ameliorates Rho-associated autosomal dominant retinitis pigmentosa. Article Snippet: Mutations in the Rhodopsin (RHO) gene are the main cause of autosomal dominant retinitis pigmentosa (adRP), 84% of which are pathogenic gain-of-function point mutations.. Treatment strategies for adRP typically involve silencing or ablating the pathogenic allele, while normal RHO protein replacement has no meaningful therapeutic benefit.. Here, we present an adenine base editor (ABE)-mediated therapeutic approach for adRP caused by RHO point mutations in vivo. Article Title: Nme 2 Cas9‐mediated therapeutic editing in inhibiting angiogenesis after wet age‐related macular degeneration onset Article Snippet: .. Briefly, 1‐μL AAV8 (9 × 10 9 VG Nme 2 Cas9 with sgRNA + 1 × 10 9 VG green fluorescent protein (GFP)) was injected into the subretinal region in the 40 s using a Article Title: Dual-AAV delivering split prime editor system for in vivo genome editing. Article Snippet: .. 1 mL AAV8 (5 109 vg N-terminal half of split-PE1024 + 5 109 vg C-terminal half of split-PE1024 + 1 109 vg GFP) was injected using a |